Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2325324rdf:typepubmed:Citationlld:pubmed
pubmed-article:2325324lifeskim:mentionsumls-concept:C1516213lld:lifeskim
pubmed-article:2325324lifeskim:mentionsumls-concept:C0376358lld:lifeskim
pubmed-article:2325324lifeskim:mentionsumls-concept:C0002199lld:lifeskim
pubmed-article:2325324lifeskim:mentionsumls-concept:C1516240lld:lifeskim
pubmed-article:2325324pubmed:issue2lld:pubmed
pubmed-article:2325324pubmed:dateCreated1990-5-24lld:pubmed
pubmed-article:2325324pubmed:abstractTextInterferon-alpha (IFN-alpha) producing capacity was measured in 47 patients with prostatic cancer by whole blood assay. The mean IFN-alpha producing capacity of prostatic cancer patients was 3657 IU/ml, which indicated a significantly (p less than 0.005) lower value than that in healthy male aged 50 years or more. IFN-alpha producing capacity in patients with Stage D disease was lower than that with Stage A, B or C. The higher the grade of the disease, the lower tended to be the capacity. A certain relationship was suspected between IFN-alpha producing capacity and the prognosis of each patient. In particular, in patients with prostatic cancer in Stage D, the prognosis was worse in low IFN-alpha producing capacity group (less than 3000 IU/ml) than in normal or high IFN-alpha producing capacity group (greater than or equal to 3000 IU/ml). It was considered that IFN-alpha producing capacity might be useful in developing the prognosis of patients with prostatic cancer.lld:pubmed
pubmed-article:2325324pubmed:languagejpnlld:pubmed
pubmed-article:2325324pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2325324pubmed:citationSubsetIMlld:pubmed
pubmed-article:2325324pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2325324pubmed:statusMEDLINElld:pubmed
pubmed-article:2325324pubmed:monthFeblld:pubmed
pubmed-article:2325324pubmed:issn0021-5287lld:pubmed
pubmed-article:2325324pubmed:authorpubmed-author:WatanabeHHlld:pubmed
pubmed-article:2325324pubmed:authorpubmed-author:NakaoMMlld:pubmed
pubmed-article:2325324pubmed:authorpubmed-author:SaitohMMlld:pubmed
pubmed-article:2325324pubmed:authorpubmed-author:NakagawaSSlld:pubmed
pubmed-article:2325324pubmed:authorpubmed-author:KishidaTTlld:pubmed
pubmed-article:2325324pubmed:authorpubmed-author:OhnishiKKlld:pubmed
pubmed-article:2325324pubmed:authorpubmed-author:OhlWWlld:pubmed
pubmed-article:2325324pubmed:authorpubmed-author:KitaMMlld:pubmed
pubmed-article:2325324pubmed:issnTypePrintlld:pubmed
pubmed-article:2325324pubmed:volume81lld:pubmed
pubmed-article:2325324pubmed:ownerNLMlld:pubmed
pubmed-article:2325324pubmed:authorsCompleteYlld:pubmed
pubmed-article:2325324pubmed:pagination262-7lld:pubmed
pubmed-article:2325324pubmed:dateRevised2011-7-28lld:pubmed
pubmed-article:2325324pubmed:meshHeadingpubmed-meshheading:2325324-...lld:pubmed
pubmed-article:2325324pubmed:meshHeadingpubmed-meshheading:2325324-...lld:pubmed
pubmed-article:2325324pubmed:meshHeadingpubmed-meshheading:2325324-...lld:pubmed
pubmed-article:2325324pubmed:meshHeadingpubmed-meshheading:2325324-...lld:pubmed
pubmed-article:2325324pubmed:meshHeadingpubmed-meshheading:2325324-...lld:pubmed
pubmed-article:2325324pubmed:meshHeadingpubmed-meshheading:2325324-...lld:pubmed
pubmed-article:2325324pubmed:meshHeadingpubmed-meshheading:2325324-...lld:pubmed
pubmed-article:2325324pubmed:meshHeadingpubmed-meshheading:2325324-...lld:pubmed
pubmed-article:2325324pubmed:year1990lld:pubmed
pubmed-article:2325324pubmed:articleTitle[Interferon-alpha producing capacities in prostatic cancer patients].lld:pubmed
pubmed-article:2325324pubmed:affiliationDepartment of Urology, Kyoto Prefectural University of Medicine.lld:pubmed
pubmed-article:2325324pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2325324pubmed:publicationTypeEnglish Abstractlld:pubmed